Business:
Gene Therapy, Devices, Biologics, Small Molecules all for DMD
Drug notes:
ABV-202 Clin0 Friedreich's ataxia; AVB-401 Clin0 dilated cardiomyopathy; undisclosed Clin0 cardiac condition
About:
Solid Biosciences is advancing genetic medicines to treat patients with neuromuscular and cardiac diseases. To create effective therapies, Solid has built a state-of-the-art process development and characterization lab to establish their transient transfection-based gene therapies. Solid’s pipeline includes SGT-003, a treatment for Duchenne muscular dystrophy and AVB-401, a treatment for BAG3-mediated dilated cardiomyopathy. As the programs progress, Solid will continue to refine their manufacturing process so that they can meet their goal of ensuring that no patient goes without therapy.
Senior Scientist, Analytical Development Boston, MA|13 days ago
Vice President, Head of Clinical R&D Boston, MA|20 days ago
Director / Senior Director, Business Development a... Boston, MA|28 days ago
Scientist II, Downstream Boston, MA|29 days ago
********* ******* ********, ******** *********** ******, **|35 days ago
Director-Gene Therapy Drug Discovery Biologist Boston, MA|51 days ago
Director, Regulatory Strategy Boston, MA|100+ days ago
Associate Director, Clinical Science Boston, MA|Not provided